Compare · GNLX vs JNJ
GNLX vs JNJ
Side-by-side comparison of Genelux Corporation (GNLX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 4733.2x GNLX ($128.7M).
- Over the past year, GNLX is down 18.5% and JNJ is up 53.9% - JNJ leads by 72.4 points.
- JNJ has been more active in the news (7 items in the past 4 weeks vs 3 for GNLX).
- JNJ has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Johnson & Johnson
- Price
- $2.87+1.41%
- $253.01+1.39%
- Market cap
- $128.7M
- $609.12B
- 1M return
- -5.44%
- +7.55%
- 1Y return
- -18.47%
- +53.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 3
- 7
- Recent ratings
- 6
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest GNLX
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Director Smither John W sold $34,898 worth of shares (12,000 units at $2.91), decreasing direct ownership by 12% to 91,403 units (SEC Form 4)
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- SEC Form 8-K filed by Genelux Corporation
- President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)
- General Counsel Groen Eric was granted 233,957 shares (SEC Form 4)
- Director Thomas John was granted 28,409 shares, increasing direct ownership by 6% to 501,193 units (SEC Form 4)
- Chief Financial Officer Pulisic Matthew was granted 278,906 shares (SEC Form 4)
- Director Tyree James L was granted 28,409 shares, increasing direct ownership by 42% to 96,483 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph was granted 174,841 shares, increasing direct ownership by 113% to 329,390 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson